Scientists Identify Enzyme That May Stop Liver Disease Progression

A team of researchers at Cedars-Sinai has made a promising discovery in the fight against one of America’s most widespread health conditions. They’ve identified an enzyme called UBE2N that appears to shield the liver from damage as metabolic dysfunction-associated steatotic liver disease (MASLD) worsens. The findings, published in Nature Metabolism, could eventually lead to new treatments for a condition that affects roughly 100 million people in the United States.

MASLD, formerly known as nonalcoholic fatty liver disease, is the most common form of liver disease in America. What makes this discovery particularly significant is the sheer number of people at risk. Of the 100 million Americans with MASLD, somewhere between 20% and 25% develop metabolic dysfunction-associated steatohepatitis (MASH), a more aggressive version characterized by inflammation, cell injury, and scarring alongside the excess liver fat.

Understanding the Mitochondrial Connection

The researchers started with a solid hunch: damaged mitochondria, the cellular structures responsible for energy production, might be driving disease progression. Their multicenter study found that UBE2N enzyme levels decline as liver disease becomes more severe. This observation turned out to be the key that unlocked a new understanding of MASH development.

“The UBE2N enzyme appears to protect the liver from the inflammation and damage associated with MASH by helping remove damaged mitochondria and supporting the breakdown of fat,” explained Dr. Ekihiro Seki, a professor of Medicine and Biomedical Sciences at Cedars-Sinai and co-corresponding author. When enzyme levels dropped, the researchers observed increased damaged cells and liver injury.

The team then tested their theory by restoring UBE2N to normal levels in laboratory mice. The results were striking. Fat accumulation decreased, inflammation reduced, and scarring improved. These outcomes suggest we might be looking at a genuine treatment target for preventing MASLD from advancing to MASH.

Why This Matters for Treatment

Current treatment approaches are limited. Most care focuses on lifestyle modifications and preventing additional damage, with no cure currently available for MASH. While some medications exist, the options remain frustratingly narrow for patients facing serious complications.

This discovery opens a different door. Rather than just managing symptoms or slowing progression, enhancing the UBE2N pathway could potentially prevent the disease from reaching dangerous stages in the first place. That’s a meaningful distinction in medicine.

Dr. Shelly Lu, director of the Karsh Division of Gastroenterology and Hepatology at Cedars-Sinai, emphasized the broader implications: “The identification of this enzyme’s role in regulating mitochondria in the liver is an important advance in understanding steatotic liver disease. Future studies can test whether enhancing this protective pathway can complement existing treatments, identify patients most likely to benefit and lead to new therapeutic approaches for preventing advanced disease.”

The Road Ahead

What we’re looking at here is preclinical research that shows genuine promise. The mouse studies worked. The mechanism makes biological sense. Now comes the harder part: translating these findings into human treatment.

Researchers will need to determine how to safely and effectively boost UBE2N levels in human patients. They’ll need to figure out which patients would benefit most. They’ll need to run clinical trials. None of this happens quickly, but the foundation is solid.

For the millions of Americans with MASLD, this represents something that’s been in short supply: genuine hope backed by rigorous science. Rather than accepting that liver disease is a one-way street leading to scarring and failure, we now have evidence that intervening at the cellular level might actually stop or reverse the damage.

This kind of discovery exemplifies why medical research matters. By understanding the fundamental biology of disease, researchers can identify intervention points that wouldn’t be obvious through observation alone. The UBE2N finding wasn’t a lucky accident; it came from thoughtful hypothesis and careful experimentation.

Source: Cedars-Sinai Health Sciences University

If boosting a single enzyme can truly prevent liver disease from becoming catastrophic, what other common diseases might have equally elegant solutions hiding in our cellular machinery?